Effects of non-starch polysaccharides on inflammatory bowel disease

International Journal of Molecular Sciences

Volumn 18, Issue 7, 2017, Pages

  Nie, Ying ^a,b   Lin, Qinlu ^a   Luo, Feijun ^a  

^a CENTRAL SOUTH UNIVERSITY OF FORESTRY AND TECHNOLOGY   (China)

^b Hunan Biological and Electromechanical Polytechnic   (China)

Author keywords

Gut microbiota; Immune system; Inflammatory bowel disease (IBD); Intervention; Mechanism; Non starch polysaccharide (NSP); Pro inflammatory cytokines; SCFAs

Indexed keywords

ALGAL EXTRACT; ARABINOXYLAN; BETA GLUCAN; CYCLINE; FUCOIDIN; GLUCAN; GUAR GUM; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; ISPAGULA; LAMINARAN; LIPOPOLYSACCHARIDE; MALONALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE; MYELOPEROXIDASE; NITRIC OXIDE; NON STARCH POLYSACCHARIDE; PECTIN; POLYSACCHARIDE; PREBIOTIC AGENT; SHORT CHAIN FATTY ACID; TOLL LIKE RECEPTOR; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; VOLATILE FATTY ACID;

ABDOMINAL PAIN; BARLEY; BIFIDOBACTERIUM; CELIAC DISEASE; CELL PROLIFERATION; CLOSTRIDIUM; COLORECTAL CANCER; CONSTIPATION; DIET SUPPLEMENTATION; ENTERITIS; ESCHERICHIA COLI; GASTROINTESTINAL REFLUX; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INTESTINAL AVAILABILITY; INTESTINE FLORA; LACTOBACILLUS; LIPID DIET; MUCILAGE; MUSHROOM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OAT BRAN; PROTEIN EXPRESSION; RECURRENCE RISK; REGULATORY T LYMPHOCYTE; REVIEW; ULCERATIVE COLITIS; WHEAT BRAN; WOUND HEALING; ANALYSIS; ANIMAL; CHEMISTRY; DIETARY FIBER; IMMUNOLOGY; MICROBIOLOGY; PATHOLOGY; THERAPEUTIC USE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DIETARY FIBER; FATTY ACIDS, VOLATILE; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; POLYSACCHARIDES;

EID: 85021310756     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18071372     Document Type: Review

References (128)

1. Kemp, R.; Dunn, E.; Schultz, M. Immunomodulators in inflammatory bowel disease: An emerging role for biologic agents. BioDrugs 2013, 27, 585–590. [CrossRef] [PubMed]
2. Nguyen, G.C.; Chong, C.A.; Chong, R.Y. National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States. J. Crohns Colitis 2014, 8, 288–295. [CrossRef] [PubMed]
3. Molodecky, N.A.; Rabi, D.M.; Ghali, W.A.; Ferris, M.; Chernoff, G.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Barkema, H.W.; Kaplan, G.G. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142, 46–54. [CrossRef] [PubMed]
4. Baumgart, D.C.; Sandborn, W.J. Inflammatory bowel disease: Clinical aspects and established and evolving therapies. Lancet 2007, 369, 1641–1657. [CrossRef]
5. Lim, W.C.; Wang, Y.; MacDonald, J.K.; Hanauer, S. Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst. Rev. 2016, 7. [CrossRef]
6. Sullivan, P.W.; Ghushchyan, V.H.; Globe, G.; Schatz, M. Oral corticosteroid exposure and adverse effects in asthmatic patients. J. Allergy Clin. Immunol. 2017. [CrossRef] [PubMed]
7. Bryant, R.V.; Brain, O.; Travis, S.P. Conventional drug therapy for inflammatory bowel disease. Scand. J. Gastroenterol. 2015, 50, 90–112. [CrossRef] [PubMed]
8. Neuman, M.G.; Nanau, R.M. Inflammatory bowel disease: Role of diet, microbiota, life style. Transl. Res. 2012, 160, 29–44. [CrossRef] [PubMed]
9. Belalcazar, L.M.; Anderson, A.M.; Lang, W.; Schwenke, D.C.; Haffner, S.M.; Yatsuya, H.; Rushing, J.; Vitolins, M.Z.; Reeves, R.; Pi-Sunyer, F.X., et al. Fiber intake and plasminogen activator inhibitor-1 in type 2 diabetes: Look AHEAD (Action for Health in Diabetes) trial findings at baseline and year 1. J. Acad. Nutr. Diet 2014, 114, 1800–1810. [CrossRef] [PubMed]
10. Lattimer, J.M.; Haub, M.D. Effects of dietary fiber and its components on metabolic health. Nutrients 2010, 2, 1266–1289. [CrossRef] [PubMed]
11. Montagne, L.; Pluske, J.R.; Hampson, D.J. A review of interactions between dietary fibre and the intestinal mucosa, and their consequences on digestive health in young non-ruminant animals. Anim. Feed Sci. Tech. 2003, 108, 95–117. [CrossRef]
12. Mendis, M.; Leclerc, E.; Simsek, S. Arabinoxylans, gut microbiota and immunity. Carbohyd. Polym. 2016, 139, 159–166. [CrossRef] [PubMed]
13. Huang, X.; Nie, S. The structure of mushroom polysaccharides and their beneficial role in health. Food Funct. 2015, 6, 3205–3217. [CrossRef] [PubMed]
14. Bobadilla, F.; Rodriguez-Tirado, C.; Imarai, M.; Galotto, M.J.; Andersson, R. Soluble β-1,3/1,6-glucan in seaweed from the southern hemisphere and its immunomodulatory effect. Carbonhyd. Polym. 2013, 92, 241–248. [CrossRef] [PubMed]
15. Schwartz, B.; Hadar, Y. Possible mechanisms of action of mushroom-derived glucan on inflammatory bowel disease and associated cancer. Ann. Transl. Med. 2014, 2, 19. [PubMed]
16. Asp, N.-G. Dietary fibre- definition, chemistry and analytical determination. Mol. Asp. Med. 1986, 9, 17–29. [CrossRef]
17. Lovegrove, A.; Edwards, C.H.; de Noni, I.; Patel, H.; El, S.N.; Grassby, T.; Zielke, C.; Ulmius, M.; Nilsson, L.; Butterworth, P.J., et al. Role of polysaccharides in food, digestion, and health. Crit. Rev. Food. Sci. Nutr. 2017, 57, 237–253. [CrossRef] [PubMed]
18. Galvez, J.; Rodriguez-Cabezas, M.E.; Zarzuelo, A. Effects of dietary fiber on inflammatory bowel disease. Mol. Nutr. Food Res. 2005, 49, 601–608. [CrossRef] [PubMed]
19. Raninen, K.; Lappi, J.; Mykkanen, H.; Poutanen, K. Dietary fiber type reflects physiological functionality: Comparison of grain fiber, inulin, and polydextrose. Nutr. Rev. 2011, 69, 9–21. [CrossRef] [PubMed]
20. Zeng, H.; Lazarova, D.L.; Bordonaro, M. Mechanisms linking dietary fiber, gut microbiota and colon cancer prevention. World J. Gastrointest. Oncol. 2014, 6, 41–51. [CrossRef] [PubMed]
21. Davies, P.S.; Rhodes, J. Maintenance of remission in ulcerative colitis with sulphasalazine or a high-fibre diet: A clinical trial. Br. Med. J. 1978, 1, 1524–1525. [CrossRef] [PubMed]
22. Hallert, C.; Nyman, M.; Pousette, A.; Granno, C.; Svensson, H. Increasing fecal butyrate in ulcerative colitis patients by diet: Controlled pilot study. Inflamm. Bowel. Dis. 2003, 9, 116–121. [CrossRef] [PubMed]
23. Suchecka, D.; Harasym, J.P.; Wilczak, J.; Gajewska, M.; Oczkowski, M.; Gudej, S.; Błaszczyk, K.; Kamola, D.; Filip, R.; Gromadzka-Ostrowska, J. Antioxidative and anti-inflammatory effects of high β-glucan concentration purified aqueous extract from oat in experimental model of LPS-induced chronic enteritis. J. Func. Foods 2015, 14, 244–254. [CrossRef]
24. Liu, B.; Lin, Q.; Yang, T.; Zeng, L.; Shi, L.; Chen, Y.; Luo, F. Oat β-glucan ameliorates dextran sulfate sodium (DSS)-induced ulcerative colitis in mice. Food Funct. 2015, 6, 3454–3463. [CrossRef] [PubMed]
25. Thies, F.; Masson, L.F.; Boffetta, P.; Kris-Etherton, P. Oats and bowel disease: A systematic literature review. Br. J. Nutr. 2014, 112, S31–S43. [CrossRef] [PubMed]
26. Forland, D.T.; Saetre, L.; Lyberg, T.; Lygren, I.; Hetland, G. Effect of an extract based on the medicinal mushroom Agaricus blazei Murill on expression of cytokines and calprotectin in patients with ulcerative colitis and Crohn’s disease. Scand. J. Immunol. 2011, 73, 66–75. [CrossRef] [PubMed]
27. Mojgan, N.; Reynolds, P.D.; Baumgartner, A.; Jerwoodc, D.; Andersona, D. Chaga mushroom extract inhibits oxidative DNA damage in lymphocytes of patients with inflammatory bowel disease. BioFactors 2007, 31, 191–200.
28. Therkelsen, S.P.; Hetland, G.; Lyberg, T.; Lygren, I.; Johnson, E. Cytokine Levels After Consumption of a Medicinal Agaricus blazei Murill-Based Mushroom Extract, AndoSan, in Patients with Crohn’s Disease and Ulcerative Colitis in a Randomized Single-Blinded Placebo-Controlled Study. Scand. J. Immunol. 2016, 84, 323–331. [CrossRef] [PubMed]
29. Shi, L.; Lin, Q.; Yang, T.; Nie, Y.; Li, X.; Liu, B.; Shen, J.; Liang, Y.; Tang, Y.; Luo, F. Oral administration of Lentinus edodes β-glucan ameliorates DSS-induced ulcerative colitis in mice via MAPK-Elk-1 and MAPK-PPARgamma pathways. Food Funct. 2016, 7, 4614–4627. [CrossRef] [PubMed]
30. Lavi, I.; Levinson, D.; Peri, I.; Nimri, L.; Hadar, Y.; Schwartz, B. Orally administered glucan from the edible mushroom Pleurotus pulmonarius reduce acute inflammation in dextran sulfate sodium-induced experimental colitis. Br. J. Nutr. 2010, 103, 393–402. [CrossRef] [PubMed]
31. Takashi, O.; Rie, K.; Yuji, N.; Itsuko, F.; Takashi, H.; Kazuki, K.; Masashi, M.; Hitoshi, A. Lentinan fromshiitake mushroom (Lentinus edodes) suppresses expression of cytochrome P450 1A subfamily in the mouse liver. BioFactors 2004, 21, 407–409.
32. Xie, J.T.; Wang, C.Z.; Wicks, S.; Yin, J.J.; Kong, J.; Li, J.; Li, Y.C.; Yuan, C.S. Ganoderma lucidum extract inhibits proliferation of SW 480 human colorectal cancer cells. Exp. Oncol. 2006, 28, 25–29. [PubMed]
33. Lavi, I.; Friesem, D.; Geresh, S.; Hadar, Y.; Schwartz, B. An aqueous polysaccharide extract from the edible mushroom Pleurotus ostreatus induces anti-proliferative and pro-apoptotic effects on HT-29 colon cancer cells. Cancer Lett. 2006, 244, 61–70. [CrossRef] [PubMed]
34. Shanmugam, M.K.; Kannaiyan, R.; Sethi, G. Targeting cell signaling and apoptotic pathways by dietary agents: Role in the prevention and treatment of cancer. Nutr. Cancer 2011, 63, 161–173. [CrossRef] [PubMed]
35. Hu, H.; Zhang, Z.; Lei, Z.; Yang, Y.; Sugiura, N. Comparative study of antioxidant activity and antiproliferative effect of hot water and ethanol extracts from the mushroom Inonotus obliquus. J. Biosci. Bioeng. 2009, 107, 42–48. [CrossRef] [PubMed]
36. Ryan, M.T.; O’shea, C.J.; Collins, C.B.; O’Doherty, J.V.; Sweeney, T. Effects of dietary supplementation with Laminaria hyperborea, Laminaria digitata, and Saccharomyces cerevisiae on the IL-17 pathway in the porcine colon. J. Anim. Sci. 2012, 30, 263–265. [CrossRef] [PubMed]
37. O’Shea, C.J.; O’Doherty, J.V.; Callanan, J.J.; Doyle, D.; Thornton, K.; Sweeney, T. The effect of algal polysaccharides laminarin and fucoidan on colonic pathology, cytokine gene expression and Enterobacteriaceae in a dextran sodium sulfate-challenged porcine model. J. Nutr. Sci. 2016, 5, e15. [CrossRef] [PubMed]
38. Lee, K.H.; Park, M.; Ji, K.Y.; Lee, H.Y.; Jang, J.H.; Yoon, I.J.; Oh, S.S.; Kim, S.M.; Jeong, Y.H.; Yun, C.H., et al. Bacterial β-(1,3)-glucan prevents DSS-induced IBD by restoring the reduced population of regulatory T cells. Immunobiology 2014, 219, 802–812. [CrossRef] [PubMed]
39. Jin, M.; Zhao, K.; Huang, Q.; Xu, C.; Shang, P. Isolation, structure and bioactivities of the polysaccharides from Angelica sinensis (Oliv.) Diels: A review. Carbohyd. Polym. 2012, 89, 713–722. [CrossRef] [PubMed]
40. Rychlik, A.; Nieradka, R.; Kander, M.; Nowicki, M.; Wdowiak, M.; Kolodziejska-Sawerska, A. The effectiveness of natural and synthetic immunomodulators in the treatment of inflammatory bowel disease in dogs. Acta. Vet. Hung. 2013, 61, 297–308. [CrossRef] [PubMed]
41. Vo, T.-S.; Kim, S.-K. Fucoidans as a natural bioactive ingredient for functional foods. J. Func. Foods 2013, 5, 16–27. [CrossRef]
42. Lean, Q.Y.; Eri, R.D.; Fitton, J.H.; Patel, R.P.; Gueven, N. Fucoidan Extracts Ameliorate Acute Colitis. PLoS ONE 2015, 10, e0128453. [CrossRef] [PubMed]
43. Kim, M.J.; Chang, U.J.; Lee, J.S. Inhibitory effects of Fucoidan in 3T3-L1 adipocyte differentiation. Mar. Biotechnol. 2009, 11, 557–562. [CrossRef] [PubMed]
44. Kim, K.-J.; Lee, B.-Y. Fucoidan from the sporophyll of Undaria pinnatifida suppresses adipocyte differentiation by inhibition of inflammation-related cytokines in 3T3-L1 cells. Nutr. Res. 2012, 32, 439–447. [CrossRef] [PubMed]
45. Fernandez, F.; Sanchez-Lombrana, J.L.; Navarro, E.; Hinojosa, J.; Gassull, M.A. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Am. J. Gastroenterol. 1999, 94, 427–433. [CrossRef] [PubMed]
46. Rodríguez-Cabezas, M.E.; Gálvez, J.; Camuesco, D.; Lorente, M.D.; Concha, A.; Martinez-Augustin, O.; Redondo, L.; Zarzuelo, A. Intestinal anti-inflammatory activity of dietary fiber (Plantago ovata seeds) in HLA-B27 transgenic rats. Clin. Nutr. 2003, 22, 463–471. [CrossRef]
47. Rodriguez-Cabezas, M.E.; Galvez, J.; Lorente, M.D.; Concha, A.; Camuesco, D.; Azzouz, S.; Osuna, A.; Redondo, L.; Zarzuelo, A. Dietary fiber down-regulates colonic tumor necrosis factor α and nitric oxide production in trinitrobenzenesulfonic acid-induced colitic rats. J. Nutr. 2002, 132, 3263–3271. [PubMed]
48. Kanauchi, O.; Mitsuyama, K.; Homma, T.; Takahama, K.; Fujiyama, Y.; Tomiyasu, N.; Toyonaga, A.; Fukuda, M.; Kojima, A.; Bamba, T. Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff: Multi-center open trial. Int. J. Mol. Med. 2003, 12, 701–704. [CrossRef] [PubMed]
49. Neyrinck, A.M.; Possemiers, S.; Druart, C.; van de Wiele, T.; de Backer, F.; Cani, P.D.; Larondelle, Y.; Delzenne, N.M. Prebiotic effects of wheat arabinoxylan related to the increase in bifidobacteria, Roseburia and Bacteroides/Prevotella in diet-induced obese mice. PLoS ONE 2011, 6, e20944. [CrossRef] [PubMed]
50. James, S.L.; Christophersen, C.T.; Bird, A.R.; Conlon, M.A.; Rosella, O.; Gibson, P.R.; Muir, J.G. Abnormal fibre usage in UC in remission. Gut 2015, 64, 562–570. [CrossRef] [PubMed]
51. Cani, P.D.; Amar, J.; Iglesias, M.A.; Poggi, M.; Knauf, C.; Bastelica, D.; Neyrinck, A.M.; Fava, F.; Tuohy, K.M.; Chabo, C., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56, 1761–1772. [CrossRef] [PubMed]
52. Chen, M.H.; Swanson, K.S.; Fahey, G.C., Jr.; Dien, B.S.; Beloshapka, A.N.; Bauer, L.L.; Rausch, K.D.; Tumbleson, M.E.; Singh, V. In vitro Fermentation of Xylooligosaccharides Produced from Miscanthus x giganteus by Human Fecal Microbiota. J. Agric. Food Chem. 2016, 64, 262–267. [CrossRef] [PubMed]
53. Ng, S.C.; Plamondon, S.; Kamm, M.A.; Hart, A.L.; Al-Hassi, H.O.; Guenther, T.; Stagg, A.J.; Knight, S.C. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflamm. Bowel Dis. 2010, 16, 1286–1298. [CrossRef] [PubMed]
54. Segarra, S.; Martinez-Subiela, S.; Cerda-Cuellar, M.; Martinez-Puig, D.; Munoz-Prieto, A.; Rodriguez-Franco, F.; Rodriguez-Bertos, A.; Allenspach, K.; Velasco, A.; Ceron, J. Oral chondroitin sulfate and prebiotics for the treatment of canine Inflammatory Bowel Disease: A randomized, controlled clinical trial. BMC Vet. Res. 2016, 12, 49. [CrossRef] [PubMed]
55. Whorwell, P.J.; Altringer, L.; Morel, J.; Bond, Y.; Charbonneau, D.; O’Mahony, L.; Kiely, B.; Shanahan, F.; Quigley, E.M. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am. J. Gastroenterol. 2006, 101, 1581–1590. [CrossRef] [PubMed]
56. O’Mahony, L.; McCarthy, J.; Kelly, P.; Hurley, G.; Luo, F.; Chen, K.; O’Sullivan, G.C.; Kiely, B.; Collins, J.K.; Shanahan, F., et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128, 541–551. [CrossRef] [PubMed]
57. Silk, D.B.; Davis, A.; Vulevic, J.; Tzortzis, G.; Gibson, G.R. Clinical trial: The effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2009, 29, 508–518. [CrossRef] [PubMed]
58. Takagi, T.; Naito, Y.; Higashimura, Y.; Ushiroda, C.; Mizushima, K.; Ohashi, Y.; Yasukawa, Z.; Ozeki, M.; Tokunaga, M.; Okubo, T., et al. Partially hydrolysed guar gum ameliorates murine intestinal inflammation in association with modulating luminal microbiota and SCFA. Br. J. Nutr. 2016, 116, 1199–1205. [CrossRef] [PubMed]
59. Hung, T.V.; Suzuki, T. Dietary fermentable fiber reduces intestinal barrier defects and inflammation in colitic mice. J. Nutr. 2016, 146, 1970–1979. [CrossRef] [PubMed]
60. Alam, N.H.; Meier, R.; Sarker, S.A.; Bardhan, P.K.; Schneider, H.; Gyr, N. Partially hydrolysed guar gum supplemented comminuted chicken diet in persistent diarrhea: A randomised controlled trial. Arch. Dis. Child 2005, 90, 195–199. [CrossRef] [PubMed]
61. Tuohy, K.M.; Kolida, S.; Lustenberger, A.M.; Gibson, G.R. The prebiotic effects of biscuits containing partially hydrolysed guar gum and fructo-oligosaccharides—A human volunteer study. Br. J. Nutr. 2007, 86, 341. [CrossRef]
62. Paul, S.P.; Barnard, P.; Edate, S.; Candy, D.C. Stool consistency and abdominal pain in irritable bowel syndrome may be improved by partially hydrolysed guar gum. J. Pediatr. Gastroenterol. Nutr. 2011, 53, 582–583. [CrossRef] [PubMed]
63. Yue, Y.; Wu, S.; Li, Z.; Li, J.; Li, X.; Xiang, J.; Ding, H.Wild jujube polysaccharides protect against experimental inflammatory bowel disease by enabling enhanced intestinal barrier function. Food Funct. 2015, 6, 2568–2577. [CrossRef] [PubMed]
64. Krylova, S.G.; Efimova, L.A.; Zueva, E.P.; Khotimchenko, M.U.; Amosova, E.N.; Razina, T.G.; Lopatina, K.A.; Khotimchenko, U.S. Gastroprotective effect of nonstarch polysaccharide calcium pectate under experimental conditions. Bull. Exp. Biol. Med. 2008, 145, 731–734. [CrossRef] [PubMed]
65. Jiang, L.M.; Nie, S.P.; Zhou, H.L.; Huang, D.F.; Xie, M.Y. Carboxymethylation enhances the maturation-inducing activity in dendritic cells of polysaccharide from the seeds of Plantago asiatica L. Int. Immunopharmacol. 2014, 22, 324–331. [CrossRef] [PubMed]
66. Pomin, V.H. Marine non-glycosaminoglycan sulfated glycans as potential pharmaceuticals. Pharmaceuticals 2015, 8, 848–864. [CrossRef] [PubMed]
67. Hedin, C.R.; McCarthy, N.E.; Louis, P.; Farquharson, F.M.; McCartney, S.; Taylor, K.; Prescott, N.J.; Murrells, T.; Stagg, A.J.; Whelan, K., et al. Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn’s disease and their unaffected siblings. Gut 2014, 63, 1578–1586. [CrossRef] [PubMed]
68. Fiocchi, C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 1998, 115, 182–205. [CrossRef]
69. Xu, X.; Yan, H.; Zhang, X. Structure and immuno-stimulating activities of a new heteropolysaccharide from Lentinula edodes. J. Agric. Food Chem. 2012, 60, 11560–11566. [CrossRef] [PubMed]
70. Yang, T.; Jia, M.; Meng, J.; Wu, H.; Mei, Q. Immunomodulatory activity of polysaccharide isolated from Angelica sinensis. Int. J. Biol. Macromol. 2006, 39, 179–184. [CrossRef] [PubMed]
71. Brown, G.D.; Gordon, S. Immune recognition of fungal β-glucan. Cell Microbiol. 2005, 7, 471–479. [CrossRef] [PubMed]
72. Zekovic, D.B.; Kwiatkowski, S.; Vrvic, M.M.; Jakovljevic, D.; Moran, C.A. Natural and modified (1→3)-β-D-glucan in health promotion and disease alleviation. Crit. Rev. Biotechnol. 2005, 25, 205–230. [CrossRef] [PubMed]
73. Shi, S.H.; Yang, W.T.; Huang, K.Y.; Jiang, Y.L.; Yang, G.L.; Wang, C.F.; Li, Y. β-glucan from Coriolus versicolor protect mice against S. typhimurium challenge by activation of macrophages. Int. J. Biol. Macromol. 2016, 86, 352–361. [CrossRef] [PubMed]
74. Berner, V.K.; duPre, S.A.; Redelman, D.; Hunter, K.W. Microparticulate β-glucan vaccine conjugates phagocytized by dendritic cells activate both naive CD4 and CD8 T cells in vitro. Cell. Immunol. 2015, 298, 104–114. [CrossRef] [PubMed]
75. Kang, G.D.; Lim, S.; Kim, D.H. Oleanolic acid ameliorates dextran sodium sulfate-induced colitis in mice by restoring the balance of Th17/Treg cells and inhibiting NF-κB signaling pathway. Int. Immunopharmacol. 2015, 29, 393–400. [CrossRef] [PubMed]
76. Hartog, A.; Belle, F.N.; Bastiaans, J.; de Graaff, P.; Garssen, J.; Harthoorn, L.F.; Vos, A.P. A potential role for regulatory T-cells in the amelioration of DSS induced colitis by dietary non-digestible polysaccharides. J. Nutr. Biochem. 2015, 26, 227–233. [CrossRef] [PubMed]
77. Choi, E.H.; Yang, H.P.; Chun, H.S. Chitooligosaccharide ameliorates diet-induced obesity in mice and affects adipose gene expression involved in adipogenesis and inflammation. Nutr. Res. 2012, 32, 218–228. [CrossRef] [PubMed]
78. Li, R.; Pavuluri, S.; Bruggeman, K.; Long, B.M.; Parnell, A.J.; Martel, A.; Parnell, S.R.; Pfeffer, F.M.; Dennison, A.J.; Nicholas, K.R., et al. Coassembled nanostructured bioscaffold reduces the expression of proinflammatory cytokines to induce apoptosis in epithelial cancer cells. Nanomedicine 2016, 12, 1397–1407. [CrossRef] [PubMed]
79. Nagao-Kitamoto, H.; Shreiner, A.B.; Gillilland, M.G., 3rd; Kitamoto, S.; Ishii, C.; Hirayama, A.; Kuffa, P.; El-Zaatari, M.; Grasberger, H.; Seekatz, A.M., et al. Functional characterization of inflammatory bowel disease-associated gut dysbiosis in gnotobiotic mice. Cell Mol. Gastroenterol. Hepatol. 2016, 2, 468–481. [CrossRef] [PubMed]
80. Knights, D.; Lassen, K.G.; Xavier, R.J. Advances in inflammatory bowel disease pathogenesis: Linking host genetics and the microbiome. Gut 2013, 62, 1505–1510. [CrossRef] [PubMed]
81. Sghir, A.; Gramet, G.; Suau, A.; Rochet, V.; Pochart, P.; Dore, J. Quantification of bacterial groups within human fecal flora by oligonucleotide probe hybridization. Appl. Environ. Microbiol. 2000, 66, 2263–2266. [CrossRef] [PubMed]
82. Stagg, A.J.; Hart, A.L.; Knight, S.C.; Kamm, M.A. The dendritic cell: Its role in intestinal inflammation and relationship with gut bacteria. Gut 2003, 51, 1522–1529. [CrossRef]
83. Martínez-Abad, B.; Garrote, J.A.; Bernardo, D.; Montalvillo, E.; Escudero-Hernández, C.; Vázquez, E.; Rueda, R.; Arranz, E. Differential immunomodulatory effects of Lactobacillus rhamnosus DR20, Lactobacillus fermentum CECT 5716 and Bifidobacterium animalis subsp. lactis on monocyte-derived dendritic cells. J. Funct. Foods 2016, 22, 300–312. [CrossRef]
84. Hart, A.L.; Lammers, K.; Brigidi, P.; Vitali, B.; Rizzello, F.; Gionchetti, P.; Campieri, M.; Kamm, M.A.; Knight, S.C.; Stagg, A.J. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 2004, 53, 1602–1609. [CrossRef] [PubMed]
85. Sokol, H.; Pigneur, B.; Watterlot, L.; Lakhdari, O.; Bermudez-Humaran, L.G.; Gratadoux, J.J.; Blugeon, S.; Bridonneau, C.; Furet, J.P.; Corthier, G., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. USA 2008, 105, 16731–16736. [CrossRef] [PubMed]
86. Wong, C.; Harris, P.J.; Ferguson, L.R. Potential benefits of dietary fibre intervention in inflammatory bowel disease. Int. J. Mol. Sci. 2016, 17, 919. [CrossRef] [PubMed]
87. De Vrese, M.; Marteau, P.R. Probiotics and prebiotics: Effects on diarrhea. J. Nutr. 2007, 137, S803–S811.
88. Wilson, B.; Whelan, K. Prebiotic inulin-type fructans and galacto-oligosaccharides: Definition, specificity, function, and application in gastrointestinal disorders. J. Gastroenterol. Hepatol. 2017, 32 (Suppl 1), 64–68. [CrossRef] [PubMed]
89. Dewulf, E.M.; Cani, P.D.; Claus, S.P.; Fuentes, S.; Puylaert, P.G.; Neyrinck, A.M.; Bindels, L.B.; de Vos, W.M.; Gibson, G.R.; Thissen, J.P., et al. Insight into the prebiotic concept: Lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 2013, 62, 1112–1121. [CrossRef] [PubMed]
90. Hopkins, M.J.; Macfarlane, G.T. Nondigestible Oligosaccharides Enhance Bacterial Colonization Resistance against Clostridium difficile in vitro. App. Environ. Microb. 2003, 69, 1920–1927. [CrossRef]
91. Hookman, P. Clostridium difficile associated infection, diarrhea and colitis. World J. Gastroenterol. 2009, 15, 1554. [CrossRef] [PubMed]
92. Barbut, F.; Jones, G.; Eckert, C. Epidemiology and control of Clostridium difficile infections in healthcare settings: An update. Curr. Opin. Infect. Dis. 2011, 24, 370–376. [CrossRef] [PubMed]
93. Perrin, S.; Warchol, M.; Grill, J.P.; Schneider, F. Fermentations of fructo-oligosaccharides and their components by Bifidobacterium infantis ATCC 15697 on batch culture in semi-synthetic medium. J. Appl. Microbiol. 2001, 90, 859–865. [CrossRef] [PubMed]
94. Falony, G.; Vlachou, A.; Verbrugghe, K.; de Vuyst, L. Cross-Feeding between Bifidobacterium longum BB536 and acetate-converting, butyrate-producing colon bacteria during growth on oligofructose. Appl. Environ. Microbiol. 2006, 72, 7835–7841. [CrossRef] [PubMed]
95. Viladomiu, M.; Hontecillas, R.; Yuan, L.; Lu, P.; Bassaganya-Riera, J. Nutritional protective mechanisms against gut inflammation. J. Nutr. Biochem. 2013, 24, 929–939. [CrossRef] [PubMed]
96. Schirmer, M.; Smeekens, S.P.; Vlamakis, H.; Jaeger, M.; Oosting, M.; Franzosa, E.A.; Jansen, T.; Jacobs, L.; Bonder, M.J.; Kurilshikov, A., et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 2016, 167, 1125–1136. [CrossRef] [PubMed]
97. Li, Y.; Oosting, M.; Smeekens, S.P.; Jaeger, M.; Aguirre-Gamboa, R.; Le, K.T.; Deelen, P.; Ricano-Ponce, I.; Schoffelen, T.; Jansen, A.F., et al. A functional genomics approach to understand variation in cytokine production in humans. Cell 2016, 167, 1099–1110. [CrossRef] [PubMed]
98. Breuer, R.I.; Buto, S.K.; Christ, M.L.; Bean, J.; Vernia, P.; Paoluzi, P.; di Paolo, M.C.; Caprilli, R. Rectal irrigation with short-chain fatty acids for distal ulcerative colitis. Preliminary report. Dig. Dis. Sci. 1991, 36, 185–187. [CrossRef] [PubMed]
99. Luhrs, H.; Gerke, T.; Muller, J.G.; Melcher, R.; Schauber, J.; Boxberge, F.; Scheppach, W.; Menzel, T. Butyrate inhibits NF-κB activation in lamina propria macrophages of patients with ulcerative colitis. Scand. J. Gastroenterol. 2002, 37, 458–466. [CrossRef] [PubMed]
100. Pacheco, R.G.; Esposito, C.C.; Muller, L.C.; Castelo-Branco, M.T.; Quintella, L.P.; Chagas, V.L.; de Souza, H.S.; Schanaider, A. Use of butyrate or glutamine in enema solution reduces inflammation and fibrosis in experimental diversion colitis. World J. Gastroenterol. 2012, 18, 4278–4287. [CrossRef] [PubMed]
101. Goldsmith, J.R.; Sartor, R.B. The role of diet on intestinal microbiota metabolism: Downstream impacts on host immune function and health, and therapeutic implications. J. Gastroenterol. 2014, 49, 785–798. [CrossRef] [PubMed]
102. Zimmerman, M.A.; Singh, N.; Martin, P.M.; Thangaraju, M.; Ganapathy, V.; Waller, J.L.; Shi, H.; Robertson, K.D.; Munn, D.H.; Liu, K. Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. Am. J. Phys. Gastrointest. Liver Phys. 2012, 302, G1405–G1415. [CrossRef] [PubMed]
103. Berni Canani, R.; Di Costanzo, M.; Leone, L. The epigenetic effects of butyrate: Potential therapeutic implications for clinical practice. Clin. Epigenetics 2012, 4, 4. [CrossRef] [PubMed]
104. Tan, J.; McKenzie, C.; Potamitis, M.; Thorburn, A.N.; Mackay, C.R.; Macia, L. The role of short-chain fatty acids in health and disease. Adv. Immunol. 2014, 121, 91–119. [PubMed]
105. Brown, A.J.; Goldsworthy, S.M.; Barnes, A.A.; Eilert, M.M.; Tcheang, L.; Daniels, D.; Muir, A.I.; Wigglesworth, M.J.; Kinghorn, I.; Fraser, N.J., et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 2003, 278, 11312–11319. [CrossRef] [PubMed]
106. Le Poul, E.; Loison, C.; Struyf, S.; Springael, J.Y.; Lannoy, V.; Decobecq, M.E.; Brezillon, S.; Dupriez, V.; Vassart, G.; van Damme, J., et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J. Biol. Chem. 2003, 278, 25481–25489. [CrossRef] [PubMed]
107. Lu, Z.; Gui, H.; Yao, L.; Yan, L.; Martens, H.; Aschenbach, J.R.; Shen, Z. Short-Chain fatty acids and acidic pH upregulate UT-B, GPR41, and GPR4 in rumen epithelial cells of goats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2015, 308, R283–R293. [CrossRef] [PubMed]
108. Kamp, M.E.; Shim, R.; Nicholls, A.J.; Oliveira, A.C.; Mason, L.J.; Binge, L.; Mackay, C.R.; Wong, C.H.G. Protein-Coupled receptor 43 modulates neutrophil recruitment during acute inflammation. PLoS ONE 2016, 11, e0163750. [CrossRef] [PubMed]
109. Kelly, C.J.; Zheng, L.; Campbell, E.L.; Saeedi, B.; Scholz, C.C.; Bayless, A.J.; Wilson, K.E.; Glover, L.E.; Kominsky, D.J.; Magnuson, A., et al. Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier Function. Cell Host Microbe 2015, 17, 662–671. [CrossRef] [PubMed]
110. Gui, H.; Shen, Z. Concentrate diet modulation of ruminal genes involved in cell proliferation and apoptosis is related to combined effects of short-chain fatty acid and pH in rumen of goats. J. Dairy Sci. 2016, 99, 6627–6638. [CrossRef] [PubMed]
111. Luceri, C.; Femia, A.P.; Fazi, M.; Di Martino, C.; Zolfanelli, F.; Dolara, P.; Tonelli, F. Effect of butyrate enemas on gene expression profiles and endoscopic/histopathological scores of diverted colorectal mucosa: A randomized trial. Dig. Liver Dis. 2016, 48, 27–33. [CrossRef] [PubMed]
112. Ye, Y.N.; Koo, M.W.; Li, Y.; Matsui, H.; Cho, C.H. Angelica sinensis modulates migration and proliferation of gastric epithelial cells. Life Sci. 2001, 68, 961–968. [CrossRef]
113. Ye, Y.N.; So, H.L.; Liu, E.S.; Shina, V.Y.; Cho, C.H. Effect of polysaccharides from Angelica sinensis on gastric ulcer healing. Life Sci. 2003, 72, 925–932. [CrossRef]
114. Zhao, H.; Luo, Y.; Lu, C.; Lin, N.; Xiao, C.; Guan, S.; Guo, D.A.; Liu, Z.; Ju, D.; He, X.; Lu, A. Enteric mucosal immune response might trigger the immunomodulation activity of Ganoderma lucidum polysaccharide in mice. Planta Med. 2010, 76, 223–227. [CrossRef] [PubMed]
115. Deters, A.M.; Schröder, K.R.; Smiatek, T.; Hensel, A. Ispaghula (Plantago ovata) seed husk polysaccharides promote proliferation of human epithelial cells (skin keratinocytes and fibroblasts) via enhanced growth factor receptors and energy production. Planta Med. 2005, 71, 33–39. [CrossRef] [PubMed]
116. Slavin, J.L.; Martini, M.C.; Jacobs, D.R.J.; Marquart, L. Plausible mechanisms for the protectiveness of whole grains. Am. J. Clin. Nutr. 1999, 70, S459–S463.
117. Ferguson, L.R.; Zhu, S.; Kestell, P. Contrasting effects of non-starch polysaccharide and resistant starch-based diets on the disposition and excretion of the food carcinogen, 2-amino-3-methylimidazo [4,5-f]quinoline (IQ), in a rat model. Food Chem. Toxicol. 2003, 41, 785–792. [CrossRef]
118. Hu, Y.; Martin, J.; Le Leu, R.; Young, G.P. The colonic response to genotoxic carcinogens in the rat: Regulation by dietary fibre. Carcinogenesis 2002, 23, 1131–1137. [CrossRef] [PubMed]
119. James, J.F.; Bruce, E.S. Clinical gastroenterology. In Inflammatory Bowel Disease Diagnosis and Therapeutics; Russell, D.C., Ed.; Humana Press: Totowa, NJ, USA, 2003; pp. 33–63.
120. Aldini, R.; Micucci, M.; Cevenini, M.; Fato, R.; Bergamini, C.; Nanni, C.; Cont, M.; Camborata, C.; Spinozzi, S.; Montagnani, M., et al. Antiinflammatory effect of phytosterols in experimental murine colitis model: Prevention, induction, remission study. PLoS ONE 2014, 9, e108112. [CrossRef] [PubMed]
121. Suchecka, D.; Harasym, J.; Wilczak, J.; Gromadzka-Ostrowska, J. Hepato- and gastro- protective activity of purified oat 1–3, 1–4-β-D-glucan of different molecular weight. Int. J. Biol. Macromol. 2016, 91, 1177–1185. [CrossRef] [PubMed]
122. Błaszczyk, K.; Wilczak, J.; Harasym, J.; Gudej, S.; Suchecka, D.; Królikowski, T.; Lange, E.; Gromadzka-Ostrowska, J. Impact of low and high molecular weight oat β-glucan on oxidative stress and antioxidant defense in spleen of rats with LPS induced enteritis. Food Hydrocoll. 2015, 51, 272–280. [CrossRef]
123. Plantago Ovata (Psyllium). Available online: http://www.altmedrev.com/publications/7/2/155.pdf (accessed on 5 May 2017).
124. Wang, R.; Sun, P.; Zhou, Y.; Zhao, X. Preventive effect of Dendrobium candidum Wall. ex Lindl. on activated carbon-induced constipation in mice. Exp. Ther. Med. 2015, 9, 563–568. [CrossRef] [PubMed]
125. Varshosaz, J.; Jaffarian Dehkordi, A.; Golafshan, S. Colon-Specific delivery of mesalazine chitosan microspheres. J. Microencapsul. 2008, 23, 329–339. [CrossRef] [PubMed]
126. Chang, D.; Lei, J.; Cui, H.; Lu, N.; Sun, Y.; Zhang, X.; Gao, C.; Zheng, H.; Yin, Y. Disulfide cross-linked nanospheres from sodium alginate derivative for inflammatory bowel disease: Preparation, characterization, and in vitro drug release behavior. Carbohydr. Polym. 2012, 88, 663–669. [CrossRef]
127. Desai, M.S.; Seekatz, A.M.; Koropatkin, N.M.; Kamada, N.; Hickey, C.A.; Wolter, M.; Pudlo, N.A.; Kitamoto, S.; Terrapon, N.; Muller, A., et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell 2016, 167, 1339–1353. [CrossRef] [PubMed]
128. Charlebois, A.; Rosenfeld, G.; Bressler, B. The impact of dietary interventions on the symptoms of inflammatory bowel disease: A systematic review. Crit. Rev. Food Sci. Nutr. 2015, 56, 1370–1378. [CrossRef] [PubMed]